STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G/A] RxSight, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Divisadero Street Capital and affiliated entities, together with William Zolezzi, report beneficial ownership of 218,918 shares of RxSight common stock, representing approximately 0.5% of the class. The filing shows no sole voting or dispositive power and reports shared voting and dispositive power over 218,918 shares, indicating coordinated control among the reporting persons rather than individual sole authority. The report states these securities are directly owned by advisory clients of Divisadero Street Capital Management and that no advisory client holds more than 5% of the class.

The filing is submitted as a Schedule 13G/A by the investment-adviser and affiliated entities and includes a joint filing agreement and an exhibit identifying the control person.

Positive
  • None.
Negative
  • None.

Insights

TL;DR Small, passive 0.5% position by Divisadero Street; unlikely to affect RxSight's control or near-term valuation.

The filing discloses 218,918 shares (≈0.5%) held with shared voting and dispositive authority and 0 shares held with sole authority. Because the holdings are directly owned by advisory clients and each client is stated not to hold more than 5%, this appears to be a routine disclosure of a passive investment position rather than an activist or controlling stake. For investors, the filing signals transparency about ownership structure but does not indicate material governance influence or a shift in control.

TL;DR Joint filing shows coordinated reporting and shared power, but the sub-5% stake limits formal governance influence.

The schedule identifies multiple affiliated reporting persons and records shared voting and dispositive power over the same block of 218,918 shares. The presence of a joint filing agreement and a control-person identification exhibit is standard where related entities coordinate. Because the position is below the 5% ownership threshold and the filing expressly states the securities are held for advisory clients, the legal and governance implication is limited: disclosure is required and provided, but no material change to board-level influence is indicated.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Divisadero Street Capital Management, LP
Signature:/s/ William Zolezzi
Name/Title:William Zolezzi/Manager
Date:08/13/2025
William Zolezzi
Signature:/s/ William Zolezzi
Name/Title:William Zolezzi/Manager
Date:08/13/2025
Divisadero Street Partners, L.P.
Signature:/s/ William Zolezzi
Name/Title:William Zolezzi/Manager
Date:08/13/2025
Divisadero Street Partners GP, LLC
Signature:/s/ William Zolezzi
Name/Title:William Zolezzi/Manager
Date:08/13/2025
Divisadero Street Capital, LLC
Signature:/s/ William Zolezzi
Name/Title:William Zolezzi/Manager
Date:08/13/2025

Comments accompanying signature: * Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his, her or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. To the extent that "ownership of 5 percent or less of a class" was indicated in Item 5, such response only applies to the Reporting Person(s) that indicated elsewhere herein that it beneficially owns five percent (5%) or less of the class.
Exhibit Information

[Exhibit A - Joint Filing Agreement] [Exhibit B - Control Person Identification]

FAQ

Who filed the Schedule 13G/A for RxSight (RXST)?

The filing was submitted by Divisadero Street Capital Management, LP; William Zolezzi; Divisadero Street Partners, L.P.; Divisadero Street Partners GP, LLC; and Divisadero Street Capital, LLC.

How many RxSight shares does Divisadero Street report owning and what percent is that?

The reporting persons disclose beneficial ownership of 218,918 shares, representing approximately 0.5% of RxSight's common stock.

Does the filer have sole voting or dispositive power over the reported shares?

No. The filing reports 0 shares with sole voting or dispositive power and 218,918 shares with shared voting and dispositive power.

Are the reported shares held on behalf of other persons?

Yes. The filing states the securities are directly owned by advisory clients of Divisadero Street Capital Management, LP, and none of those advisory clients owns more than 5% of the class.

What exhibits accompany the Schedule 13G/A filing?

The filing references Exhibit A - Joint Filing Agreement and Exhibit B - Control Person Identification.
Rxsight, Inc.

NASDAQ:RXST

RXST Rankings

RXST Latest News

RXST Latest SEC Filings

RXST Stock Data

400.06M
38.59M
5.56%
96.93%
13.31%
Medical Devices
Ophthalmic Goods
Link
United States
ALISO VIEJO